169 related articles for article (PubMed ID: 33011650)
1. Novel acyl carbamates and acyl / diacyl ureas show in vitro efficacy against Toxoplasma gondii and Cryptosporidium parvum.
Li K; Grooms GM; Khan SM; Hernandez AG; Witola WH; Stec J
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():80-90. PubMed ID: 33011650
[TBL] [Abstract][Full Text] [Related]
2. Activity of (1-benzyl-4-triazolyl)-indole-2-carboxamides against Toxoplasma gondii and Cryptosporidium parvum.
Khan SM; Garcia Hernandez A; Allaie IM; Grooms GM; Li K; Witola WH; Stec J
Int J Parasitol Drugs Drug Resist; 2022 Aug; 19():6-20. PubMed ID: 35462232
[TBL] [Abstract][Full Text] [Related]
3. Boromycin Has Potent Anti-
Abenoja J; Cotto-Rosario A; O'Connor R
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468470
[No Abstract] [Full Text] [Related]
4. Nullscript inhibits Cryptosporidium and Toxoplasma growth.
Murakoshi F; Bando H; Sugi T; Adeyemi OS; Nonaka M; Nakaya T; Kato K
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():159-166. PubMed ID: 33120250
[TBL] [Abstract][Full Text] [Related]
5. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box.
Bessoff K; Spangenberg T; Foderaro JE; Jumani RS; Ward GE; Huston CD
Antimicrob Agents Chemother; 2014 May; 58(5):2731-9. PubMed ID: 24566188
[TBL] [Abstract][Full Text] [Related]
6. Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against
Khan SM; Bajwa MR; Lahar RY; Witola WH
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0056923. PubMed ID: 37655889
[No Abstract] [Full Text] [Related]
7. Stable expression of mucin glycoproteins GP40 and GP15 of Cryptosporidium parvum in Toxoplasma gondii.
Li M; Sun X; Chen H; Li N; Feng Y; Xiao L; Guo Y
Parasit Vectors; 2024 Feb; 17(1):65. PubMed ID: 38360646
[TBL] [Abstract][Full Text] [Related]
8. Anti-protozoal activity of Thymol and a Thymol ester against Cryptosporidium parvum in cell culture.
Dominguez-Uscanga A; Aycart DF; Li K; Witola WH; Andrade Laborde JE
Int J Parasitol Drugs Drug Resist; 2021 Apr; 15():126-133. PubMed ID: 33647675
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum.
Nava MG; Calderón F; Fernández E; Ballell L; Bamborough P; Vinayak S
Microbiol Spectr; 2023 Feb; 11(1):e0387422. PubMed ID: 36533912
[TBL] [Abstract][Full Text] [Related]
10. Selective and potent urea inhibitors of cryptosporidium parvum inosine 5'-monophosphate dehydrogenase.
Gorla SK; Kavitha M; Zhang M; Liu X; Sharling L; Gollapalli DR; Striepen B; Hedstrom L; Cuny GD
J Med Chem; 2012 Sep; 55(17):7759-71. PubMed ID: 22950983
[TBL] [Abstract][Full Text] [Related]
11. Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.
Li K; Nader SM; Zhang X; Ray BC; Kim CY; Das A; Witola WH
PLoS Pathog; 2019 Jul; 15(7):e1007953. PubMed ID: 31356619
[TBL] [Abstract][Full Text] [Related]
12. Apicomplexan parasites are attenuated by low-energy electron irradiation in an automated microfluidic system and protect against infection with Toxoplasma gondii.
Finkensieper J; Mayerle F; Rentería-Solís Z; Fertey J; Makert GR; Lange F; Besecke J; Schopf S; Poremba A; König U; Standfest B; Thoma M; Daugschies A; Ulbert S
Parasitol Res; 2023 Aug; 122(8):1819-1832. PubMed ID: 37233817
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and In Vivo Activities of Sulfur-Containing Linear Bisphosphonates against Apicomplexan Parasites.
Szajnman SH; Galaka T; Li ZH; Li C; Howell NM; Chao MN; Striepen B; Muralidharan V; Moreno SN; Rodriguez JB
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895021
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
Kuhlenschmidt TB; Rutaganira FU; Long S; Tang K; Shokat KM; Kuhlenschmidt MS; Sibley LD
Antimicrob Agents Chemother; 2016 Jan; 60(1):570-9. PubMed ID: 26552986
[TBL] [Abstract][Full Text] [Related]
15. Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase.
Gorla SK; Kavitha M; Zhang M; Chin JE; Liu X; Striepen B; Makowska-Grzyska M; Kim Y; Joachimiak A; Hedstrom L; Cuny GD
J Med Chem; 2013 May; 56(10):4028-43. PubMed ID: 23668331
[TBL] [Abstract][Full Text] [Related]
16. Dual Transcriptomics To Determine Gamma Interferon-Independent Host Response to Intestinal Cryptosporidium parvum Infection.
Gallego-Lopez GM; Mendoza Cavazos C; Tibabuzo Perdomo AM; Garfoot AL; O'Connor RM; Knoll LJ
Infect Immun; 2022 Feb; 90(2):e0063821. PubMed ID: 34928716
[TBL] [Abstract][Full Text] [Related]
17. Apicomplexan infections in the gut.
Wilhelm CL; Yarovinsky F
Parasite Immunol; 2014 Sep; 36(9):409-20. PubMed ID: 25201405
[TBL] [Abstract][Full Text] [Related]
18. A conserved coccidian gene is involved in Toxoplasma sensitivity to the anti-apicomplexan compound, tartrolon E.
Bowden GD; Reis PM; Rogers MB; Bone Relat RM; Brayton KA; Wilson SK; Di Genova BM; Knoll LJ; Nepveux V FJ; Tai AK; Ramadhar TR; Clardy J; O'Connor RM
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():1-7. PubMed ID: 32738587
[TBL] [Abstract][Full Text] [Related]
19. (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth.
Moreno B; Bailey BN; Luo S; Martin MB; Kuhlenschmidt M; Moreno SN; Docampo R; Oldfield E
Biochem Biophys Res Commun; 2001 Jun; 284(3):632-7. PubMed ID: 11396947
[TBL] [Abstract][Full Text] [Related]
20. Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae.
Brophy VH; Vasquez J; Nelson RG; Forney JR; Rosowsky A; Sibley CH
Antimicrob Agents Chemother; 2000 Apr; 44(4):1019-28. PubMed ID: 10722506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
